Corvus Pharma
(NASDAQ:CRVS)
$1.7807
-0.0093[-0.52%]
At close: Mar 28
$1.7807
0[0.00%]
After Hours: 4:15PM EDT
Consensus Rating1
Buy
Highest Price Target1
$10.00
Lowest Price Target1
$3.50
Consensus Price Target1
$6.25

Corvus Pharma Stock (NASDAQ:CRVS), Analyst Ratings, Price Targets, Predictions

Corvus Pharmaceuticals Inc has a consensus price target of $6.25, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from Mizuho, Oppenheimer, and Cantor Fitzgerald on March 27, 2024, March 20, 2024, and September 7, 2023. With an average price target of $4.83 between Mizuho, Oppenheimer, and Cantor Fitzgerald, there's an implied 171.43% upside for Corvus Pharmaceuticals Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Mar
1
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Mizuho
Oppenheimer
Cantor Fitzgerald
Mizuho
Ladenburg Thalmann

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Corvus Pharma

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/27/2024CRVSBuy Now
Corvus Pharma
$1.7896.55%Mizuho
Graig Suvannavejh
$3.5 → $3.5MaintainsNeutralGet Alert
03/20/2024CRVSBuy Now
Corvus Pharma
$1.78293.1%Oppenheimer
Jeff Jones
$8 → $7MaintainsOutperformGet Alert
09/07/2023CRVSBuy Now
Corvus Pharma
$1.78124.63%Cantor Fitzgerald
Li Watsek
→ $4ReiteratesOverweight → OverweightGet Alert
06/16/2023CRVSBuy Now
Corvus Pharma
$1.7896.55%Mizuho
Mara Goldstein
→ $3.5ReiteratesNeutral → NeutralGet Alert
05/30/2023CRVSBuy Now
Corvus Pharma
$1.78461.58%Ladenburg Thalmann
Aydin Huseynov
$4 → $10MaintainsBuyGet Alert
05/09/2023CRVSBuy Now
Corvus Pharma
$1.78124.63%Cantor Fitzgerald
Li Watsek
$2 → $4MaintainsOverweightGet Alert
03/30/2023CRVSBuy Now
Corvus Pharma
$1.7896.55%Mizuho
Mara Goldstein
→ $3.5Reiterates → NeutralGet Alert
10/07/2022CRVSBuy Now
Corvus Pharma
$1.7812.32%Ladenburg Thalmann
Aydin Huseynov
→ $2Initiates → BuyGet Alert
12/03/2021CRVSBuy Now
Corvus Pharmaceuticals
$1.78349.26%Cantor FitzgeraldMaintainsOverweightGet Alert
12/01/2021CRVSBuy Now
Corvus Pharmaceuticals
$1.78349.26%Jefferies
Roger Song
Initiates → BuyGet Alert
08/03/2021CRVSBuy Now
Corvus Pharmaceuticals
$1.7896.55%Mizuho
Mara Goldstein
MaintainsNeutralGet Alert
07/16/2021CRVSBuy Now
Corvus Pharmaceuticals
$1.78236.95%HC Wainwright & Co.
Swayampakula Ramakanth
MaintainsBuyGet Alert
05/27/2021CRVSBuy Now
Corvus Pharmaceuticals
$1.78461.58%Cantor FitzgeraldInitiates → OverweightGet Alert

FAQ

Q

What is the target price for Corvus Pharma (CRVS)?

A

The latest price target for Corvus Pharma (NASDAQ: CRVS) was reported by Mizuho on March 27, 2024. The analyst firm set a price target for $3.50 expecting CRVS to rise to within 12 months (a possible 96.55% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Corvus Pharma (CRVS)?

A

The latest analyst rating for Corvus Pharma (NASDAQ: CRVS) was provided by Mizuho, and Corvus Pharma maintained their neutral rating.

Q

When was the last upgrade for Corvus Pharma (CRVS)?

A

There is no last upgrade for Corvus Pharma.

Q

When was the last downgrade for Corvus Pharma (CRVS)?

A

There is no last downgrade for Corvus Pharma.

Q

When is the next analyst rating going to be posted or updated for Corvus Pharma (CRVS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corvus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corvus Pharma was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.

Q

Is the Analyst Rating Corvus Pharma (CRVS) correct?

A

While ratings are subjective and will change, the latest Corvus Pharma (CRVS) rating was a maintained with a price target of $3.50 to $3.50. The current price Corvus Pharma (CRVS) is trading at is $1.78, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch